在肺腺癌进展中通过MAPK/ERK通路对hsa-miR-140-3p和CKS1B相关性的多维分析
Kexin Luo1,2,3, Meihan Liu1,4,3, Yaoshu Song1,4,3
1Affiliated Hospital of North Sichuan Medical College, Nanchong, People's Republic of China.
Discover oncology
|October 31, 2025
概括
循环素依赖激酶子单元1B (CKS1B) 驱动肺腺癌 (LUAD) 的进展和免疫逃避. 准CKS1B和MAPK/ERK信号可能会改善LUAD患者的免疫治疗和化疗抵抗结果.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- 循环素依赖激酶子单元1B (CKS1B) 在肺腺癌 (LUAD) 中被上调,与不良的临床结果相关.
- 高CKS1B表达与晚期瘤阶段,侵袭性病理和免疫细胞透有关,这表明它在免疫逃避中起作用.
研究的目的:
- 研究CKS1B在LUAD进展中的作用,其与瘤微环境的关联,以及其作为治疗点的潜力.
- 探索CKS1B的调节机制,包括它与MAPK/ERK信号传递和microRNA通路的相互作用.
- 开发基于CKS1B表达的LUAD患者生存预测模型.
主要方法:
- 定量实时聚合酶连锁反应和西部斑分析,以确认CKS1B在LUAD细胞系中的表达.
- 小干扰RNA (siRNA) 来淘汰CKS1B并评估其对细胞增殖,细胞亡,入侵和上皮细胞-介质细胞过渡 (EMT) 的影响.
- 生物信息分析以确定CKS1B,hsa-miR-140-3p,瘤突变负担 (TMB),免疫检查点和患者存活率之间的相关性;为生存预测构建名图.
主要成果:
- CKS1B的淘汰减少了LUAD细胞的增殖,增加了细胞灭绝,并抑制了入侵和EMT.
- CKS1B敲击抑制了MAPK/ERK信号通路的激活.
- 升高的hsa-miR-140-3p与CKS1B表达和改善的生存率有负相关性;在LUAD中观察到CKS1B促进剂甲基化降低.
- 一个整合CKS1B表达的诺米图有效地预测了患者的生存概率.
结论:
- CKS1B是LUAD进展的关键驱动因素,促进瘤生长,入侵和免疫逃避.
- 准CKS1B和MAPK/ERK信号通路是一个潜在的策略,可以提高免疫疗法的疗效,并克服LUAD中的化疗抵抗.
- CKS1B表达作为一个有价值的预后生物标志物,用于在LUAD患者个性化风险评估.
相关概念视频
01:07MAPK Signaling Cascades
7.9K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.9K
01:19Interactions Between Signaling Pathways
7.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.2K
03:03mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
01:22PI3K/mTOR/AKT Signaling Pathway
5.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.3K